Seer (SEER) investor relations material

Strategic positioning and market opportunity

• Positioned at the forefront of proteomics, enabling deep, unbiased, and scalable data for precision medicine and AI-driven drug discovery.

• Addressing a fast-growing total addressable market projected to reach $23B by 2034, with consumables growing at a 36% CAGR.

• Proteomics is becoming foundational for large-scale population studies and biopharma R&D, surpassing genomics in clinical utility for complex diseases.

• Platform adoption is expanding globally, with a diversified customer base including leading academic, government, and biopharma partners.

Technology and innovation

• Proteograph platform delivers >7x more data points per sample than competing platforms, enabling deeper biological insights.

• Demonstrated ability to identify thousands of novel protein quantitative trait loci (pQTLs) not previously reported.

• Platform supports population-scale studies, with over 58,000 annual sample shipments and 63% CAGR in sample volume.

• Innovation pipeline includes software workflow and minority ownership in PrognomiQ, expanding end-market potential.

Financial performance and outlook

• FY'25 revenue reached $16.6M, with a 51% gross margin and a net loss of $73.6M.

• Cash, cash equivalents, and investments totaled ~$209.5M as of Q2'26, with no debt and a 36% decrease in annual cash burn.

• Free cash flow improved year-over-year, and share repurchase program reduced outstanding shares by ~15%.